ENU-Induced Glioma Model Service

The ENU-induced glioma model achieves something no other chemically induced brain tumor system can claim, a near-100% tumor incidence from a single transplacental exposure, combined with a finely resolved progression profile from hyperplasia to invasive glioma. Alfa Cytology delivers this neuro-oncology workhorse as a full-service program, managing timed-pregnancy breeding, carcinogen administration, longitudinal MRI surveillance, and stage-graded neuropathology so that sponsors can study glioma biology and intervention across every developmental stage of the disease.

Overview of ENU-Induced Glioma Model

The story of the ENU glioma model begins in the late 1960s with the demonstration that a single intravenous injection of N-ethyl-N-nitrosourea into a pregnant rat could sentence every one of her offspring to a brain tumor. ENU is a direct-acting, short-lived alkylating agent whose hallmark lesion, O⁶-ethylguanine, is removed from DNA far more slowly in nervous tissue than elsewhere in the body; this persistence, first correlated with neuro-specific carcinogenesis in classic experiments, explains why a compound delivered to the dam expresses its mutagenicity almost exclusively in the fetal central nervous system. Affected pathways include p53, Ha-ras, neu/erbB-2, and Braf, and the target cell is the proliferating neuroepithelium of the subventricular zone, whose daughters form glial-lineage tumors that begin as microscopic clusters and mature over months.

Fig 1. Schematic of ENU-induced model workflow — transplacental/neonatal ENU exposure, de novo tumor development in the offspring brain, derivation of cell lines, and downstream heterotopic (subcutaneous) or orthotopic (intracerebral) allografting. (Lenting, Krissie, et al., 2017)

What makes the model uniquely valuable is the precision with which its natural history has been documented. Tumorigenesis passes through discrete, measurable stages: hyperplastic foci in young animals, expanding cellular clusters of under 500 µm by roughly ten to twelve weeks of age, microtumors below 1 mm, medium tumors of 1–2 mm, and finally gross tumors exceeding 2 mm, all arising with multiple lesions per brain and essentially complete penetrance. Histologically the tumors traverse the human spectrum from oligodendroglioma and mixed oligoastrocytoma through anaplastic glioma toward glioblastoma-like histology in aged animals, and extraneural lesions such as malignant schwannomas bearing neu/erbB-2 mutations appear in parallel. Adult animals, tellingly, do not develop tumors from ENU, and mice require additional genetic manipulation, underscoring that the model's power lies in capturing the vulnerability of the developing brain. Because the tumor burden can be followed non-invasively by MRI from about four months of age, and because interventions from calorie restriction to anti-angiogenic agents have been benchmarked against its staged growth, the ENU model remains the reference platform for preclinical neuro-oncology carried out in vivo.

Principles of ENU-Induced Glioma Model Construction

The ENU model's reliability rests on four foundations: the developmental timing of exposure, the DNA-repair asymmetry that concentrates damage in the brain, the staged natural history of lesions, and disciplined longitudinal monitoring. The governing elements are tabulated below.

Our Services

Because the ENU model begins before its subjects are born, it punishes improvisation and rewards planning, which is why Alfa Cytology pairs every engagement with timed-mating logistics, written dosing calendars for the dams, and pre-registered MRI and sacrifice schedules that keep months-long studies perfectly synchronized.

Workflow of ENU-Induced Glioma Model Construction

An ENU glioma study is a two-generation project: carcinogen delivery to timed-pregnant dams, followed by a year or more of observation in the offspring, punctuated by imaging and staged sacrifices. The operational sequence is as follows.

1. Study design and strain selection: The sponsor's objectives determine the rat strain, typically F344 or Sprague-Dawley for MRI compatibility, the gestational day of exposure, group sizes, and the therapeutic or chemoprevention arms to be tested during tumor progression.
2. Timed mating program: Breeder pairs are assembled and monitored so that gestational age is known precisely, since the carcinogen must be delivered within a narrow developmental window; pregnancy is confirmed and dams assigned to dosing cohorts.
3. Baseline assessment of dams: Pregnant dams are weighed and clinically assessed, and baseline condition is documented to normalize any pregnancy-related variables before carcinogen exposure.
4. ENU administration: A freshly prepared ENU solution in distilled water or saline is administered to the dam as a single intravenous injection at the protocol dose on the designated gestation day, with prepared solution used promptly given the compound's ~20-minute half-life.
5. Parturition and offspring rearing: Dams deliver normally, litters are standardized for size, and offspring are reared under controlled conditions with regular weighing; general health, neurological signs, and behavioral changes are monitored throughout development.
6. Randomization and intervention scheduling: Offspring are weaned, genotyped or ear-marked as required, and randomized to control and treatment groups; test articles, dietary regimens such as calorie restriction, or candidate therapeutics are administered on the sponsor-defined schedule aligned to tumor stage.
7. Longitudinal MRI surveillance: Beginning at approximately four months of age, cohorts undergo T2-weighted MRI at protocol intervals to detect intracranial tumors, measure their volumes, and calculate individual growth rates for in-life efficacy assessment.
8. Endpoint euthanasia and neuropathological analysis: At the final time point or upon predefined neurological endpoints, animals are euthanized, brains are harvested and fixed, and lesions are staged histologically from hyperplasia through glioma subtypes with confirmation by GFAP, Ki-67, and lineage-marker immunohistochemistry, alongside neu/erbB-2 analysis of any schwannomas.

Fig 2. ENU-Induced Glioma Model Construction Workflow.

Case Study-ENU-Induced Glioma Model Development

Alfa Cytology has supported ENU-based preclinical programs addressing dietary intervention, chemopreventive strategies, and anti-angiogenic evaluation, exploiting the model's complete penetrance and its staged progression profile to assign mechanism to specific tumor phases. These engagements have delivered MRI-quantified tumor growth curves, stage-resolved histopathology across the glioma spectrum, and supporting molecular analyses, all generated under synchronized longitudinal schedules. Prospective partners are welcome to request further information on representative study architectures and data outputs under appropriate confidentiality arrangements.

Why Choose Alfa Cytology?

A model whose timeline begins with timed pregnancies and ends a year later demands a partner built for long-horizon precision, and Alfa Cytology meets that demand end to end.

• Timed-mating and gestational-window logistics executed with day-level precision.
• Freshly prepared, rapidly administered ENU dosing that respects the compound's short half-life.
• MRI-synchronized study calendars enabling in-life tumor growth measurement rather than single endpooints.
• Stage-resolved neuropathology spanning hyperplasia through glioma subtypes with GFAP and Ki-67 panels.
• Intervention scheduling aligned to documented tumor stages for clean mechanism attribution.
• Ph.D.-level neuro-oncology leadership carrying single-point accountability across the full study arc.

Contact Us

For a glioma platform whose near-certain tumor induction and staged natural history have anchored neuro-oncology research for half a century, Alfa Cytology is ready to serve as your execution partner. Contact us or reach out to our scientific team today to design your ENU-induced glioma study and receive a customized quotation for your preclinical program.

For research use only. Not intended for any clinical use.